Open AccessELEVATED SERUM α‐HYDROXYBUTYRATE DEHYDROGENASE IN PATIENTS WITH OVARIAN CARCINOMA
Author(s) -
Kikuchi Yoshihiro,
Momose Eiko,
Kizawa Isao,
Kuki Eiichi,
Kato Koichi
Publication year - 1985
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016348509156361
Subject(s) - medicine , ovarian cancer , ovarian carcinoma , lactate dehydrogenase , ovarian tumor , ovary , cancer , carcinoma , benign tumor , gastroenterology , endocrinology , pathology , enzyme , biology , biochemistry
. To differentiate between ovarian carcinoma and benign ovarian tumor, we compared a‐hydroxybutyrate de‐hydrogenase (HBD), lactate dehydrogenase (LDH) and its isoenzyme activities in serum in 115 patients with ovarian carcinoma and benign ovarian tumor. Both serum HBD activity and total LDH activity in ovarian cancer patients were significantly (p< 0.001) higher than that in patients with benign ovarian tumor. From analysis of serum LDH isoen‐zymes, a significant decrease in LDH‐1, and significant increases in LDH‐4 and LDH‐5 in ovarian cancer patients were observed, when compared with those in patients with benign ovarian tumor. When the ovarian cancer mass could be removed surgically, a significant decrease in the HBD was observed, suggesting that the HBD might fairly reflect the tumor burden. Serum HBD activities in a half of ovarian cancer patients were higher than the mean + 2 SD of those in benign control subjects.